HDAC
28 articles
Medicinal ChemistryJournal of Medicinal Chemistry
Hydrazide-based degraders hit HDAC3 selectively without killing cells
- Built from the HDAC3-preferential inhibitor FL-007, comparing two linker exit vectors; the best series keeps only modest class I enzyme inhibition yet degrades HDAC3 selectively.
- Degradation was confirmed by immunoblot and HiBiT/LgBiT reporter assays in several cancer lines, with high maximal depletion.
- No cytotoxicity at high doses, even in non-cancerous cells; HDAC3 loss only partly re-sensitized cisplatin-resistant cells, tied to increased H3 acetylation and p21.
The interesting puzzle is where the selectivity originates. Alkyl hydrazides bind HDAC1, 2 and 3 alike, so the discrimination probably arises in the ternary complex, through how well ubiquitination geometry fits each isoform. A non-degrading hydrazide control, a ligase-dead analogue and HDAC1/2 proteomics would separate these explanations and show how wide the window really is.
Medicinal ChemistryThe Journal of Organic Chemistry
Late-stage olefination gives cyclic tetrapeptide natural products as HDAC1-selective inhibitors
- A Horner-Wadsworth-Emmons olefination diversifies the pendant tail of a cyclic tetrapeptide late in the synthesis, avoiding soluble heavy metals.
- The route gave two natural products and two analogues with a designed oxygenation pattern in the tail.
- All four inhibited HDAC1 over HDAC4 and HDAC6, though selectivity differed; the extra oxygen lowered potency and selectivity.
- Conformational and docking work suggested binding favors one ring conformation, and that the added oxygen contributes little to HDAC1 binding.
Beating HDAC4 and HDAC6 is the easy bar; for a class I selectivity claim I would want HDAC2 and HDAC3 data, which I don't see here. The oxygen that adds little to binding yet costs potency is a useful negative SAR, so I'd probe the tail with lipophilic rather than polar edits next.
Medicinal ChemistryJournal of Medicinal Chemistry
Dual SIRT6/HDAC inhibitor S20 targets pancreatic cancer metastasis
- SIRT6 and classical HDACs cooperate in epithelial-mesenchymal transition, motivating a single molecule that hits both to curb metastasis.
- Merging pharmacophores and optimizing a lead with weak potency and poor metabolic stability produced S20.
- S20 outperformed the lead and SAHA in cell migration, shifted EMT markers toward an epithelial state, and had a much longer intravenous half-life.
- In mice it dose-dependently reduced liver metastasis with a favorable safety profile.
Merging a NAD-dependent sirtuin pharmacophore with a zinc-binding HDAC one is a hard polypharmacology brief, and the molecule risks bloat. Without matched single-target controls I can't tell which arm drives the reduced liver metastasis, so I'd separate SIRT6 from HDAC inhibition cleanly before trusting the dual rationale.
Medicinal ChemistryEuropean Journal of Medicinal Chemistry
Indolizine cap group delivers a selective HDAC6 inhibitor that calms neuronal inflammation
- The authors used an indolizine as a new cap group within the standard HDAC pharmacophore and made a 13-member series.
- SAR showed that decorating the cap group is key to balancing potency and isoform selectivity; indostat (5g) emerged as the best compound, with balanced solubility, stability and lipophilicity.
- In hippocampal neurons stimulated with poly(I:C), indostat lowered IL-6 secretion and normalized the rise in HDAC6 activity.
- Anti-inflammatory effect matched pan-HDAC inhibitor SAHA, with better cellular tolerability.
Matching SAHA on IL-6 is a low bar for a selective HDAC6 compound; I'd add a tubastatin-type benchmark and HDAC6 knockdown to show the effect is on-target. Indolizine is an easy cap to decorate, but electron-rich ring systems can be oxidation-prone, so I'd check oxidative and photostability early.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Mitochondria-Homing HDAC3 Inhibitor Curbs Weight Gain and Fat Buildup in Obese Mice
- Attaching a TPP group to a classic HDAC pharmacophore steers HDAC3 inhibitors into mitochondria, where obesity-linked dysfunction disrupts fat burning.
- Structure-guided optimization yielded H18, a potent HDAC3 blocker that accumulates preferentially in mitochondria.
- In 3T3-L1 adipocytes, H18 limited lipid buildup, restored ATP and lowered oxidative stress.
- In diet-induced obese mice it cut weight gain and improved glucose handling, outperforming BG45.
Before I believed the phenotype is HDAC3 inhibition in mitochondria, I'd want a non-TPP analog and a TPP-linked inactive control: cationic TPP conjugates can themselves depolarize membranes and perturb respiration, which could mimic the ATP and oxidative-stress benefits. Also check isoform selectivity (HDAC1/2) and whether mitochondrial HDAC3 is the real target, plus tolerability and clearance of a lipophilic cation in chronic dosing.
PharmacologyBiochemical Pharmacology
Celastrol's Chemoproteomic Target in NK/T Lymphoma Is the NCOR2–HDAC3 Complex
- Celastrol cut viability of EBV-positive NK/T-cell lymphoma lines and slowed a short-term xenograft with more apoptosis markers.
- Chemical proteomics pulled down the corepressor NCOR2 near its deacetylase-activation domain; celastrol weakened NCOR2–HDAC3 association and inhibited recombinant HDAC3/NCOR2 activity.
- The result was shifted H3K27 acetylation, lipid-metabolic and stress transcriptional changes; an HDAC3 inhibitor partly reproduced them.
Celastrol is a notoriously promiscuous electrophile, so a pull-down hit is where target validation starts, not ends. NCOR2 depletion partly changing the response helps, but an HDAC3 inhibitor only partially phenocopying says other targets are involved. I'd want a non-reactive analogue as a control, in vivo dosing beyond a short xenograft, and an exposure check, since celastrol's narrow therapeutic window is its long-standing problem.
Medicinal ChemistryEuropean Journal of Medicinal Chemistry (Elsevier)
HDAC/proteasome dual inhibitor X26 improves on its parent in solid-tumor models
- Starting from the earlier lead ZY-2, the team varied the foot-pocket group, linker and terminal aryl to build new HDAC/proteasome dual inhibitors.
- X17 emerged as the potent dual hit, and deprotecting it gave X26, which keeps strong proteasome inhibition and prefers HDAC2 over HDAC1 while sparing HDAC6 and HDAC8.
- X26 was much more antiproliferative than ZY-2, notably in triple-negative MDA-MB-231 cells, with antitumor activity in solid tumor models.
Class I HDAC selectivity inside a single molecule is rare, and HDAC2 over HDAC1 is a real differentiator. Dual-target molecules have a balance problem, though: proteasome potency far above HDAC potency makes it effectively a proteasome inhibitor with a liability. I'd want matched single-target controls to show the combination is what drives cell killing.
Medicinal ChemistryEuropean Journal of Medicinal Chemistry (Elsevier)
One molecule hits both HDAC and the proteasome, outperforming its parent in breast cancer models
- Starting from the earlier lead ZY-2, the foot pocket binder, linker and terminal aryl group were varied systematically to build a dual HDAC/proteasome series.
- Deprotecting hit X17 gave X26, which keeps strong proteasome inhibition and leans toward HDAC2 over HDAC1, with good selectivity against HDAC6 and HDAC8.
- X26 was far more potent than ZY-2 against cancer cells, notably triple-negative MDA-MB-231, suppressing colonies, triggering apoptosis and DAMP release linked to immunogenic cell death.
- In an MDA-MB-231 xenograft it beat ZY-2.
Dual HDAC/proteasome pharmacology is hard to attribute: with one scaffold hitting both, the xenograft win over ZY-2 could come from either arm or from synergy. I'd want matched single-target controls and a bortezomib plus HDAC inhibitor combination as the benchmark. I'd also confirm the HDAC2 lean holds in cells, and check exposure, since a freshly unmasked polar group often hurts PK.
Medicinal ChemistryBioorganic & Medicinal Chemistry
Pyrazolopyrimidine scaffold yields dual PI3K/HDAC6 inhibitors active across breast cancer subtypes
- Pairing PI3K and HDAC inhibition on a pyrazolo[3,4-d]pyrimidine core targets crosstalk between the PI3K/AKT pathway and epigenetic dysregulation in breast cancer.
- Lead compound 13k inhibits PI3Kα at sub-micromolar potency and HDAC6 at low-nanomolar potency; pharmacophore modeling, docking and molecular dynamics rationalized the SAR.
- In ER+, HER2+ and triple-negative lines it curbed proliferation, migration and invasion, and triggered apoptosis and G1 arrest; predicted ADMET looked drug-like.
Unlike CUDC-907, which hits class I HDACs plus PI3K, 13k leans on HDAC6, a cleaner and likely better-tolerated profile if the selectivity holds. But I'd want a PI3Kα/β/δ/γ and HDAC1/2/3 panel, plus cellular readouts (p-AKT, acetyl-tubulin versus acetyl-H3) to prove on-target engagement. Cell data in three subtypes with only predicted ADMET means hydroxamate PK and mutagenicity are still untested.
PharmacologyBritish Journal of Pharmacology
Tadalafil curbs lung fibrosis in rats by blocking epithelial-mesenchymal transition through a PKG-HDAC2 route
- In rat models of lung fibrosis induced by bleomycin or paraquat, daily tadalafil lessened fibrosis and lung injury, including when treatment began at an advanced stage.
- Benefit appeared to run through cGMP/PKG signalling, dampening TGF-β/Smad activity and epithelial-mesenchymal transition.
- Preliminary data point to PKG lowering HDAC2; silencing or inhibiting HDAC2 mimicked the drug, while overexpressing it reversed the effect. The authors suggest clinical evaluation for repurposing.
Tadalafil's appeal is a known human safety profile, but PDE5 inhibitors have already been tried in fibrotic lung disease with modest signal, so the rat data need to beat that history. Bleomycin and paraquat resolve spontaneously and poorly mimic human IPF; I'd want exposure at the efficacious dose compared with human levels, plus HDAC2 and EMT readouts in patient-derived lung fibroblasts or tissue.
Medicinal ChemistryJournal of Medicinal Chemistry
Dual HDAC and PD-1/PD-L1 inhibitors tackle resistant melanoma
- Six hybrids combine histone deacetylase inhibition with PD-1/PD-L1 blockade in one molecule.
- Two leads differ in isoform preference, HDAC6-selective versus HDAC1-3; both disrupt the checkpoint pair and lower tumor cell viability in vitro.
- The HDAC6 lead eased T cell exhaustion, boosted neutrophil and NK activity in vivo, and worked in BRAF-mutant melanoma, including vemurafenib-resistant cells.
- The HDAC1-3 lead was cytotoxic but raised PD-L1 expression, so isoform choice matters.
Set against dosing an HDAC inhibitor alongside a checkpoint antibody, one hybrid sidesteps PK mismatch but pays in size and lipophilicity, with a hydroxamate warhead on a biphenyl-type PD-L1 binder. PD-1/PD-L1 disruption needs confirming by HTRF and a cellular assay. The PD-L1 rise from the HDAC1-3 lead is a useful warning; HDAC6 looks the series to push.
Medicinal ChemistryEuropean Journal of Medicinal Chemistry
Entinostat-based PROTACs preferentially degrade HDAC3 in colorectal cancer models
- Two PROTAC series were built on the HDAC inhibitor entinostat, recruiting either VHL or CRBN E3 ligases.
- A representative from each series drove time-dependent HDAC loss, favouring HDAC3, followed by apoptosis and lower viability in colorectal cancer models.
- Activity was tested in patient-derived organoids and a CAM model, with p21 and the stemness markers CD44 and LGR5 probing acetylation-driven gene regulation.
Preferential HDAC3 loss may partly reflect the entinostat warhead's own isoform profile, so the first things to look for are a non-binding or inactive-epimer control and a way to separate degradation from inhibition, such as HDAC3 knockout or proteasome and neddylation blockade. A comparison with other HDAC3-selective PROTACs would also show whether the VHL versus CRBN choice shapes isoform bias.
Medicinal ChemistryEuropean Journal of Medicinal Chemistry
Marine-derived anthranilamides turn out to be selective HDAC6 inhibitors for colitis
- A marine natural product was optimized at multiple positions into anthranilamide analogues for inflammatory bowel disease.
- The lead compound curbed IL-6 and IL-1β in cells and proved a selective HDAC inhibitor, favoring HDAC6 over HDAC1.
- Docking proposed its HDAC6 binding mode, and it eased colonic damage in a DSS colitis mouse model.
A preference for HDAC6 over HDAC1 is notable, but docking alone shouldn't settle it. A full isoform panel and a cellular readout comparing tubulin and histone acetylation would test it. Whether the anti-inflammatory effect is on-target is a separate question, answerable with an HDAC6 knockout or tool-inhibitor control; binding kinetics of the zinc-binding group may also shape isoform selectivity.
Medicinal ChemistryEuropean Journal of Medicinal Chemistry
Selective HDAC11 inhibitor PB151 curbs liver cancer by rewiring lipid metabolism
- Structure-guided design yielded PB151, a potent HDAC11 inhibitor with strong selectivity against other HDAC isoforms.
- In liver cancer cells it engages HDAC11, raises levels of the substrate SHMT2, slows proliferation and triggers apoptosis.
- In an orthotopic mouse model, injected PB151 shrank tumor burden, extended survival and spared liver architecture without overt toxicity.
- Mechanistically it activates LKB1-AMPK signaling, lowers FASN and raises ACC1 phosphorylation, limiting lipid accumulation.
HDAC11 is the one isoform where selectivity is cheap to claim and hard to earn, since its fatty-acyl deacylase pocket differs from classic zinc-hydrolase HDACs. If PB151 really clears the other isoforms, that beats most hydroxamate-type tool compounds. But SHMT2 rising is the only engagement readout, and the LKB1-AMPK story looks downstream and possibly off-target. I'd want a cellular thermal shift and an inactive analog first; parenteral dosing also says little about oral exposure.
Medicinal ChemistryJournal of Medicinal Chemistry
Non-cytotoxic HDAC3-selective degraders built on a propyl hydrazide zinc-binder
- Class I HDAC degraders were designed from the HDAC3-preferring inhibitor FL-007, using a propyl hydrazide zinc-binding group and testing two linker exit vectors.
- The compounds inhibited HDAC1, HDAC2 and HDAC3 to varying degrees yet selectively depleted HDAC3, shown by immunoblotting and HiBiT/LgBiT assays across several cell lines.
- They were not cytotoxic in cancer or normal cells; HDAC3 loss gave a modest cisplatin-sensitizing effect in resistant cells, weaker than with cytotoxic inhibitors, tracking with higher histone H3 acetylation and p21.
Degradation decoupled from inhibition here: compounds still hit HDAC1/2 yet only HDAC3 disappears, so the linker exit vector, not the ZBG, is steering isoform selectivity. That's the useful lesson for ternary-complex design. But non-cytotoxic plus weak cisplatin sensitization suggests HDAC3 scaffolding loss alone is a soft phenotype. I'd want a catalytic-dead rescue before believing a degrader advantage.
Medicinal ChemistryJournal of Medicinal Chemistry
Silicon-containing tubastatin A analogs yield selective HDAC3 inhibitor for liver fibrosis
- Tubastatin A was redesigned by changing both the cap group and the zinc-binding motif, introducing silicon-containing alkyl hydrazides to steer selectivity toward HDAC3.
- Lead compound 6b inhibited HDAC3 at low-nanomolar potency with clear selectivity over HDAC5, HDAC6 and HDAC8, and docking supported the binding mode. It showed antifibrotic effects in TGF-β-stimulated stellate and sinusoidal endothelial cell models, with favorable ADMET properties.
- In a CCl4 mouse liver fibrosis model, 6b lowered liver enzymes and fibrosis markers and improved histology, outperforming tubastatin A and nintedanib; it appeared to act by dampening TGF-β/Smad signaling via altered histone acetylation.
Changing both cap and zinc binder on an HDAC6-leaning scaffold and ending up HDAC3-selective is a clever pivot, and a silicon alkyl hydrazide is a chemotype I would happily add to my own collection. Still, I doubt docking alone proves the selectivity, and hydrazides raise metabolic and safety questions under chronic dosing. Beating nintedanib in a single CCl4 model encourages without settling anything.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Adamantane-capped indole hydroxamate YP200 pushes HDAC11 selectivity into a lung cancer PDX model
- Starting from the earlier lead PB94, the authors optimized the core, linker and cap of an indole-based hydroxamic acid series against HDAC11.
- The best compound, YP200, combines a secondary-amine linker with an adamantane surface-recognition cap.
- It showed high potency for HDAC11 with strong selectivity over other HDAC isoforms, and suppressed tumor growth in a patient-derived NSCLC xenograft.
Hydroxamates are rarely clean across isoforms, so a bulky adamantane cap doing the selectivity work is the part I'd chase: it suggests HDAC11's narrow channel rewards cap size more than zinc-binder tweaks. Given the recent probe-validity debate around HDAC11 tools, I'd want kinetic isoform panels and cellular target engagement before trusting the efficacy story.
Medicinal ChemistryACS Chemical Biology (ACS)
Elevenostat is a multi-HDAC inhibitor biased to HDAC6, not an HDAC11-selective probe
- Re-testing Elevenostat (JB3-22) against recombinant HDAC isoforms with two orthogonal HDAC11 assays showed only weak HDAC11 inhibition.
- Full HDAC1–11 profiling found much stronger inhibition of HDAC6 and HDAC10, plus class I enzymes, with HDAC11 the least sensitive isoform.
- Cellular readouts (tubulin and histone acetylation, reduced viability) matched HDAC6 and class I engagement, so past HDAC11 conclusions drawn from this compound need re-reading.
This is the unglamorous but valuable kind of paper: a compound used as an HDAC11 tool turns out to hit HDAC6 hardest. Any phenotype published with Elevenostat now has an attribution problem. Before I reuse an inhibitor as a probe, I want full-panel selectivity and a matched inactive control, which this case argues for.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Co-crystal-guided HDAC6 inhibitors that reach the L2 loop and trigger autophagy in lung cancer cells
- Second-generation HDAC6 inhibitors were designed from X-ray structures of earlier compounds bound to the zebrafish HDAC6 catalytic domain.
- Co-crystal structures of two leads showed engagement of S531 in the L2 loop; cells showed raised acetylated tubulin without a clear histone acetylation change.
- One lead cut A549 viability in 2D and 3D culture through pro-autophagic signalling and also affected phase-separation behaviour.
Grabbing the L2 loop is the obvious handle for isoform selectivity: the CD2 pocket is conserved, the loop is not. Acetylated tubulin up and histones flat is the readout I want before believing a selectivity claim. I'd still ask for a broad HDAC panel and some PK before getting excited about the autophagy story.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
First thiazolamide PI4KIIIβ/HDAC dual inhibitors take a host-directed route against HCV
- Host-directed dual inhibition of PI4KIIIβ and HDACs had not previously been reported for hepatitis C, where resistance to direct-acting antivirals remains a concern.
- A series of thiazolamide-based dual inhibitors was designed, synthesised and evaluated.
- Lead compounds showed potent enzymatic inhibition of both targets together with anti-HCV activity.
With DAAs curing most patients, the case for a host-directed HCV drug is hard to make commercially, and a dual PI4KIIIβ/HDAC profile adds tox risk. I read this as a good exercise in multitarget design, but would want to see cytotoxicity and kinase selectivity before calling the window real.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Millepachine hybrid hits tubulin and HDAC8 together in ovarian cancer models
- The natural product millepachine was fused with a key HDAC-inhibitor pharmacophore to build dual tubulin/HDAC inhibitors.
- Lead compound 6 was broadly antiproliferative across 12 cancer lines, inhibited tubulin polymerisation and HDAC8, and was selective for HDAC8 over HDAC1, 4 and 6.
- It suppressed tumour growth in an ovarian cancer xenograft with a favourable safety profile.
HDAC8 is a less crowded choice than the usual HDAC6/class I pairing, and pairing it with a tubulin binder is mechanistically coherent. My worry is the classic one for dual hybrids: the two activities rarely scale together, so I'd want evidence that HDAC8 inhibition, not just the tubulin arm, contributes to the in vivo effect.
Medicinal ChemistrychemRxiv
Longer semi-rigid linkers drive VHL-based HDAC6 degraders with antileukemic activity
- A solid-phase route enabled systematic variation of VHL ligand, exit vector and linker in vorinostat-derived HDAC6 PROTACs.
- Longer, semi-rigid linkers gave the best degradation; the lead compounds degraded HDAC6 preferentially in MM.1S and MV4-11 cells.
- A matched non-degrading control with similar HDAC inhibition was clearly less antiproliferative, pointing to degradation itself as the driver.
The non-degrading control with matched enzyme inhibition is the kind of experiment that separates degradation from plain inhibition, and it favors the PROTAC. Preferential, not exclusive, HDAC6 selectivity from a vorinostat-like warhead is the weak point; a more isoform-selective ligand might sharpen it.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Binding kinetics help isolate HDAC2-selective inhibitor KTT-1
- KTT-1 (compound 12) was identified as HDAC2-selective by evaluating both thermodynamics and kinetics of enzyme–inhibitor binding, rather than affinity alone.
- Crystallography of HDAC2 with the compound, plus quantum chemical calculations on model compounds, suggests its 2-furanyl group drives the selectivity.
- In cells it preferentially inhibited HDAC2 over the highly homologous HDAC1 and promoted neurite outgrowth; in stress-vulnerable mice it improved memory and depression-like behavior.
Screening on residence time rather than IC50 alone is how you get past the near-identical HDAC1/2 active sites, and a furanyl contact backed by both crystallography and QM is a clean, testable rationale. Cellular HDAC2-over-HDAC1 preference is rare, so I'd want it confirmed in neurons with real brain exposure.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
A '2-in-1' PROTAC Folds the Cereblon Ligand into the HDAC8 Cap to Shrink the Degrader
- Instead of tethering two ligands, the cereblon-binding motif is built into the capping group of an HDAC8 inhibitor, so one structural element engages both proteins.
- Versus the group's first-generation degrader, the compact analogs are smaller, more selective and more drug-like.
- They degrade HDAC8 potently in vivo.
Most of us accept PROTAC bulk as a tax; fusing the E3 ligand into the warhead's cap group attacks that directly and is a transferable idea for other zinc-enzyme targets. The question I'd press is whether the shared motif compromises either binding event or cereblon neosubstrate selectivity. If in vivo degradation holds with better properties, the 'linkerless' direction deserves more attention.
Medicinal ChemistryACS Medicinal Chemistry Letters (ACS)
Iron(II)-Activatable Conjugates Enable Tumor-Conditional Release of the HDAC Inhibitor Panobinostat
- Hydroxamic acid-based HDAC inhibitors are limited by poor selectivity among metalloenzymes and by genotoxicity risk linked to isocyanate metabolites.
- The study applies a previously reported iron(II)-activatable conjugate platform to cage the pan-HDAC inhibitor panobinostat, aiming for tumor-conditional payload release.
- In multiple myeloma cell line models, the conjugate successfully caged HDAC inhibitory activity, and a bioisosteric control conjugate showed reduced genotoxicity relative to the free hydroxamate.
- Follow-up investigation identified the carboxylesterase CES1 as responsible for unexpected proteolytic instability of the panobinostat conjugate observed both in vitro and in vivo.
- The finding is noted as a focus for future work toward mitigating hydroxamate-associated toxicity and mutagenicity through more robust tumor-conditional activation.
Caging panobinostat's hydroxamate behind an Fe(II) trigger is a sensible fix for the isocyanate-genotoxicity liability that's dogged this chemotype, and the bioisosteric control actually showing lower genotoxicity than free drug is the kind of data I'd want before calling any HDACi "safer." But what grabs me is the CES1 finding: an esterase chewing through the conjugate in vitro and in vivo is the failure mode a clean MM cell assay never warns you about. That's not a footnote — it's the design problem for the next iteration, whether you engineer around the CES1 recognition motif or add orthogonal masking. I'd rather see this reported now than discovered in an IND package; it's a useful cautionary data point for anyone building Fe(II)-activatable payloads beyond this one hydroxamate.
Medicinal ChemistryACS Medicinal Chemistry Letters (ACS)
New Selective HDAC4/HDAC7 Inhibitors Offer Chemical Probes for Th17 Biology
- HDAC4 and HDAC7 — two class IIa histone deacetylases with tissue-restricted expression — were recently identified as distinct transcriptional drivers of Th17 cell differentiation.
- Using the class IIa scaffold TMP269 as a starting point, researchers designed and synthesized a new series of HDAC4/7-targeted inhibitors.
- Structure-guided optimization of the metal-proximal and hydrophobic-binding regions yielded analogs with improved potency and greater isoform selectivity.
- Luciferase transcriptional assays, protein-binding studies, and docking analyses revealed distinct SAR patterns that separately govern selectivity for HDAC4 versus HDAC7.
- The resulting compounds offer selective chemical probes for dissecting HDAC4 and HDAC7 function in Th17 biology and a foundation for future therapies targeting Th17-driven inflammatory disease, including IBD.
Class IIa HDACs are pseudo-catalytic with shallow, promiscuous pockets — TMP269 already buys you pan-IIa selectivity over class I/IIb almost for free, so the real fight here is splitting HDAC4 from HDAC7, and that's the part I'd actually flag. Their catalytic domains are near-identical; selectivity has to come from second-shell/rim contacts in the hydrophobic channel, not the zinc-binding group, so decoupling the metal-chelating SAR from the selectivity-driving SAR (as they describe) is the right strategy and not trivial to execute. As probes, these look solid — potency plus genuine paralog discrimination is exactly what's needed to deconvolute Th17 phenotypes cleanly, though I'd want permeability/off-target data before trusting cellular calls. Going after Th17/IBD instead of the usual oncology playground is the smarter long game too: pan-HDACi toxicity is a dealbreaker for chronic dosing, and isoform-restricted engagement is the only realistic path to a tolerable chronic immunomodulator.
Medicinal ChemistryACS Medicinal Chemistry Letters (ACS)
Chemists Engineer Isoform-Selective HDAC4/HDAC7 Probes to Dissect Th17 Inflammation
- HDAC4 and HDAC7 are class IIa histone deacetylases with limited tissue expression, making them attractive, more selective epigenetic drug targets than broadly expressed HDAC family members.
- Both enzymes help drive the transcriptional program behind Th17 cell differentiation, a pathway linked to inflammatory bowel disease and other Th17-associated inflammatory conditions.
- Chemists reworked the metal-binding and hydrophobic contact regions of TMP269, a known class IIa scaffold, to build a new series of HDAC4/7-directed analogs.
- Reporter-gene, binding, and docking studies uncovered distinct structural features that separately steer potency toward HDAC4 versus HDAC7.
- The work delivered isoform-selective, potent compounds usable as chemical probes to separately study HDAC4 and HDAC7 function, and as starting points for Th17-targeted therapeutics.
Class IIa HDACs are the pseudo-catalytic oddballs of the family — barely any intrinsic deacetylase activity, so their biology runs largely through protein contacts rather than a clean catalytic pocket, which is why generic HDAC pharmacophores rarely discriminate them well. Building off TMP269 instead of starting de novo is the pragmatic call: it's a validated class IIa binder, so tuning the metal-binding warhead plus the adjacent hydrophobic contacts is a much more tractable SAR exercise than blind discovery. Pulling HDAC4 vs HDAC7 selectivity out of that is the real win — these two are highly homologous, and clean separation is notoriously hard. Most clinical HDAC drugs are pan- or Class I-selective, so isoform-pure IIa probes are genuinely useful tool compounds for picking apart Th17 biology, well before anyone's thinking about a lead.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
One Molecule, Two Jobs: A Compact PROTAC Strategy for Degrading HDAC8
- Researchers describe a "2-in-1" PROTAC design that merges the CRBN-recruiting ligand into the capping group of an HDAC8 warhead, rather than linking two separate ligands.
- This lets one structural motif engage both HDAC8 and the CRBN E3 ligase, unlike conventional heterobifunctional PROTACs, whose separate POI- and E3-binding units plus linker often yield large, poorly drug-like molecules.
- Relative to the team's earlier HDAC8 degrader YX862, the new compact degraders show improved selectivity, lower molecular weight, and better overall drug-like properties.
- The compounds also achieved effective HDAC8 degradation in vivo, indicating therapeutic potential beyond cell-based activity.
- The study proposes a broader design framework for building smaller, more efficient PROTACs by integrating target engagement and E3 ligase recruitment into a single motif.
The move that catches my eye: folding the CRBN ligand into the HDAC8 warhead's capping group instead of bolting on a full separate E3 unit plus linker. That's a direct attack on the MW/logP bloat that tanks oral exposure in most heterobifunctional degraders — not incremental linker trimming, a structural collapse of the whole ternary-complex scaffold. Going from YX862 to these analogs with better selectivity AND lower MW (rarely a package deal) says the capping vector is actively shaping the HDAC8–CRBN interface, not just shedding atoms. In vivo degradation data is the sanity check I always want before trusting a compact-PROTAC claim. I'd want SAR around that fused cap next — how much substituent tolerance before CRBN engagement drops off. Feels like a real template for smaller, more drug-like degraders, not just this target.